Shaping Your Advocacy Strategy: Trends and drivers in today’s advocacy relations
More than ever before, pharma has been seeking and is expected to integrate real-world perspectives and expertise of patients and patient groups across the entire drug development continuum. Earlier and greater engagement leads to more meaningful clinical endpoints, improved recruitment and retention rates, and a better understanding of treatment preferences, among a myriad of other benefits.
For many companies, however, uncertainty still exists around how to accomplish this. MK&A’s senior vice president, Ellen Coleman, MPH shares five specific tips companies can take to incorporate the patient voice within their clinical development process.
|Challenge #1: Difficulty aligning internal teams on engagement strategy
||Challenge #2: Clinical development ready for patient protocol input now
|Challenge #3: What does it mean to really be patient centric?
||Challenge #4: How does the patient advocacy function adapt to changes?
|Challenge #5: Evaluating, prioritizing and centralizing stakeholder information
Back to Full Blog List